Sandoz agrees to drop generic in Omeros clash

30-07-2018

Sandoz agrees to drop generic in Omeros clash

galitskaya / iStockphoto.com

Sandoz has agreed to postpone its generic version of a cataract surgery drug made by biopharmaceutical company Omeros, ending a patent infringement lawsuit between the two in Delaware.


Sandoz, Omeros, patent, ANDA, FDA, cataract surgery, settlement, Omidria, patent litigation,

LSIPR